E. I. du Pont de Nemours and Company (DuPont) - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1998, and the six-month period ended on the same date. DuPont operates across multiple industry segments including Chemicals, Fibers, Polymers, Petroleum, Life Sciences, and Diversified Businesses. The filing reflects unaudited financial statements and management's discussion of results.
Key Financial Metrics
| Metric | Q2 1998 | Q2 1997 | 6M 1998 | 6M 1997 |
|---|---|---|---|---|
| Sales | $11,140M | $11,402M | $22,105M | $22,613M |
| Net Income | $959M | $1,140M | $1,865M | $2,160M |
| Diluted EPS | $0.83 | $0.99 | $1.62 | $1.88 |
| Cash from Operations | N/A | N/A | $1,868M | $2,175M |
| Total Debt | $16.0B | N/A | $16.0B | $12.1B (Year-end 1997) |
| Cash & Equivalents | $3,371M | N/A | $3,371M | $1,004M (Year-end 1997) |
| Current Ratio | 0.9 | N/A | 0.9 | 0.8 (Year-end 1997) |
Note: Q2 1998 diluted EPS of $0.83 includes nonrecurring charges of $0.04 per share. Adjusted EPS before nonrecurring items was $0.87.
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 2% in Q2 1998 and 2% for the six months ended June 30, 1998, compared to the prior year.
- Profitability Pressure: Net income fell 16% in Q2 and 14% for the six-month period. Earnings before taxes dropped 22% in Q2.
- Segment Performance:
- Petroleum: Underlying earnings dropped 27% due to a 30% decline in crude oil prices (averaging $12.37/barrel).
- Fibers: Earnings were down 9% excluding nonrecurring charges, impacted by competitive pressure on "Dacron" polyester.
- Chemicals: After-tax income declined 4% despite a 1% sales increase.
- Life Sciences: Earnings rose 3% driven by agricultural products, offset by pharmaceutical expenses.
- Debt and Liquidity: Total debt increased by $3.9 billion to $16.0 billion, primarily due to commercial paper issuance to finance working capital and acquisitions. Cash balances increased significantly to $3.37 billion in anticipation of the DuPont Merck buyout.
Guidance, Outlook, and Risks
- Outlook: Management expects third-quarter results to be below the prior year's third quarter, citing continued challenging business conditions.
- Acquisitions and Divestitures:
- DuPont Merck: DuPont acquired Merck's 50% interest in the pharmaceutical joint venture for $2.6 billion in July 1998. A pretax charge of $1.0 to $1.6 billion related to in-process R&D is expected in Q3 1998.
- Conoco Divestiture: DuPont announced plans to divest its Conoco energy business via an IPO expected in the second half of 1998. A noncash compensation charge of $150M-$200M is anticipated upon completion.
- ICI Acquisitions: Final acquisitions of ICI's titanium dioxide and Pakistan polyester resins businesses (approx. $800M total) are expected in Q4 1998.
- Legal Proceedings: Significant ongoing litigation includes "Benlate" 50 DF fungicide claims (crop damage, personal injury, and securities fraud) and environmental penalties related to Conoco pipeline operations. Accruals are recorded, but adverse changes could result in future charges.
- Year 2000 Compliance: Estimated out-of-pocket costs range from $300M to $400M, with completion targeted for mid-1999.
Investor Verification Checklist
- Verify the impact of the $1.0B-$1.6B in-process R&D charge related to the DuPont Merck acquisition on Q3 1998 earnings.
- Monitor the timeline and execution of the Conoco Inc. IPO and subsequent divestiture strategy.
- Assess the sensitivity of the Petroleum segment to continued low crude oil prices.
- Review the status of "Benlate" litigation settlements and potential for additional accruals.
- Confirm the completion of the remaining ICI acquisitions and their integration impact.